Smith & Nephew consensus takes shape, shares trade steadily in London

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 11:31.

Smith & Nephew (GB0009223206) opens the week with a clear analyst consensus around its London listing. The medical technology group’s shares trade on the London Stock Exchange, and recent data show a Hold rating on average with a moderate implied upside according to major aggregators.

What analysts currently say

MarketBeat reports that Smith & Nephew carries a consensus Hold rating from covering analysts, with an average price target of about 1,382.63 pence, compared with a recent share price around 1,138.50 pence on the London Stock Exchange. This suggests a potential upside in the mid-teens percentage range based on that dataset. The site also notes a market capitalization near £12.5 billion and a dividend yield close to 3.7 percent, highlighting the combination of income and moderate expected capital appreciation. For investors tracking valuation, the same source lists a price-to-earnings ratio of roughly 41, reflecting expectations of continued earnings growth in the medical devices segment. Additional consensus pages such as MarketScreener similarly show a mixed but broadly neutral stance on the stock, with buy, hold and sell recommendations distributed across major houses.

How recent results frame expectations

Investegate publishes Smith & Nephew’s detailed fourth quarter and full year 2025 results, showing revenue of $1,702 million in Q4 2025, an 8.3 percent reported increase versus the prior year, and full-year revenue of $6,164 million, up 6.1 percent. The same release highlights a reported operating profit of $794 million for 2025, up 20.7 percent, and free cash flow of $840 million, a strong 52.5 percent rise compared with 2024. According to the company, this performance reflects the completion of its 12-Point Plan aimed at improving growth and margins and positions the group for a further step-up in returns. These numbers form the backdrop for current analyst models, as research houses factor the stronger profitability and cash generation into their medium-term forecasts for orthopedics, sports medicine and advanced wound management.

The business behind the forecasts

Smith & Nephew generates most of its revenue from three main segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management, supplying implants, instruments and biologics to hospitals worldwide. A representative product line is its knee replacement systems, used in orthopedic surgery to restore joint function and reduce pain in patients with advanced arthritis. These implants, together with hip replacement devices and trauma hardware, are central to the company’s long-term growth story as aging populations drive demand for joint reconstruction procedures.

Where the shares trade today

Smith & Nephew shares (GB0009223206) last traded on the London Stock Exchange at around 1,138.50 pence, based on MarketBeat data as of 2026-06-26, with a market capitalization near £12.5 billion. The stock therefore reflects both the group’s improved 2025 profitability and the current Hold consensus from covering analysts.

Disclaimer: This text is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of any transaction. All data are based on sources cited in the article and may change over time.